Forge Biologics’ $120 Million Series B Financing

Wilson Sonsini Goodrich & Rosati advised RA Capital Management on the deal.

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced the closing of a $120 million Series B financing. The financing was led by RA Capital Management with participation from Perceptive Advisors and related affiliates, Surveyor Capital (a Citadel company), Octagon Capital, and Marshall Wace. Existing investors Perceptive Xontogeny Venture Fund and Drive Capital also participated. Forge will use the proceeds of this Series B financing to accelerate the expansion of its AAV manufacturing CDMO capabilities with cGMP production capacity, as well as operate its subsidiaries that are advancing novel AAV gene therapy programs.

The Wilson Sonsini Goodrich & Rosati team included: Jennifer Fang (Picture) , Amanda Creedon, Tamara Labanowski, Michael Hostetler, Christina Susanto, Alyson Nickols, Sherrie Holdman, Ryan Lin, Morgan Brown, Ryan Greecher, Sara Pollock, Gregory Broome and Andrew Bryant. 

Involved fees earner: Gregory Broome – Wilson Sonsini Goodrich & Rosati; Morgan Brown – Wilson Sonsini Goodrich & Rosati; Andrew Bryant – Wilson Sonsini Goodrich & Rosati; Christina Susanto – Wilson Sonsini Goodrich & Rosati; Amanda Creedon – Wilson Sonsini Goodrich & Rosati; Jennifer Fang – Wilson Sonsini Goodrich & Rosati; Ryan Greecher – Wilson Sonsini Goodrich & Rosati; Sherrie Holdman – Wilson Sonsini Goodrich & Rosati; Michael Hostetler – Wilson Sonsini Goodrich & Rosati; Tamara Labanowski – Wilson Sonsini Goodrich & Rosati; Ryan Lin – Wilson Sonsini Goodrich & Rosati; Alyson Nickols – Wilson Sonsini Goodrich & Rosati; Sara Pollock – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: RA Capital Management;

Author: Martina Bellini